Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Phase 3

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: AMG 386 Placebo
Drug: AMG 386
Drug: Paclitaxel

First Posted Date: 2010-09-17

Last Posted Date: 2016-12-15

Lead Sponsor: Amgen

Target Recruit Count: 919

Registration Number: NCT01204749

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer Female

Interventions: Drug: Iniparib (SAR2405550 -BSI-201)
Drug: paclitaxel

First Posted Date: 2010-09-17

Last Posted Date: 2017-03-22

Lead Sponsor: Sanofi

Target Recruit Count: 141

Registration Number: NCT01204125

Locations: 🇫🇷
Investigational Site Number 250002, Toulouse, France
🇫🇷
Investigational Site Number 250001, Besancon Cedex, France
🇫🇷
Investigational Site Number 250004, Bordeaux, France

and more 22 locations

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Genasense
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2010-09-13

Last Posted Date: 2016-02-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT01200342

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: CS-7017
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-09-10

Last Posted Date: 2020-07-07

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT01199055

Locations: 🇰🇷
Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Biological: Pelareorep

First Posted Date: 2010-09-10

Last Posted Date: 2020-09-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 108

Registration Number: NCT01199263

Locations: 🇺🇸
Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
🇺🇸
Hurley Medical Center, Flint, Michigan, United States

and more 33 locations

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Paclitaxel
Drug: Saracatinib
Drug: Matched placebo

First Posted Date: 2010-09-08

Last Posted Date: 2015-05-05

Lead Sponsor: University College, London

Target Recruit Count: 107

Registration Number: NCT01196741

Locations: 🇬🇧
St Bartholomew's Hospital, London, Greater London, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
🇬🇧
University College London Hospital, London, Greater London, United Kingdom

and more 9 locations

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Clear Cell Cystadenocarcinoma
Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Temsirolimus

First Posted Date: 2010-09-08

Last Posted Date: 2019-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT01196429

Locations: 🇺🇸
Cadence Cancer Center in Warrenville, Warrenville, Illinois, United States
🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 142 locations

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3

Completed

Conditions: Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Stage IIA Esophageal Cancer AJCC v7
Stage IIB Esophageal Cancer AJCC v7
Stage IIIA Esophageal Cancer AJCC v7
Stage IB Esophageal Cancer AJCC v7
Stage IIIB Esophageal Cancer AJCC v7

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery
Biological: Trastuzumab

First Posted Date: 2010-09-08

Last Posted Date: 2023-09-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 203

Registration Number: NCT01196390

Locations: 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 628 locations

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Sorafenib
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2010-09-03

Last Posted Date: 2016-10-18

Lead Sponsor: Emory University

Target Recruit Count: 25

Registration Number: NCT01194869

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Cancer

Interventions: Drug: Temsirolimus
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Sorafenib

First Posted Date: 2010-08-23

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 278

Registration Number: NCT01187199

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy